Cardiovascular and Cerebrovascular Diseases, Chronic Respiratory Diseases, Endocrine and Metabolic Diseases, Malignant Tumors, Multimorbidities
Conditions
Keywords
Multimorbidities, Epidemiological survey, Cohort, Population medicine
Brief summary
The Chinese Population Health and Multimorbidity Study (CPHMS; initially named China Pulmonary Health Study, CPHS) was a large-scale epidemiological survey designed to investigate the pulmonary health of Chinese adults aged 20 years or older leveraging a multistage stratified sampling scheme between 2011 and 2014 in mainland China. Briefly, a total number of 57,779 local residents were recruited from 10 representative provinces and municipalities and were invited to participate in the study. A final number of 50,991 adults who met the major inclusion criteria could be considered in further analyses. In order to investigate the changes of pulmonary health and disease status (e.g. occurrence and development of chronic respiratory diseases and other important relevant multimorbidities, lung function indices, etc.) and corresponding impact factors in the CPHMS study population, we plan to initiate the first round of follow-up investigation between 2025 and 2027 (planned) , i.e. more than 10 years after the baseline survey.
Interventions
None listed
Sponsors
China-Japan Friendship Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* (1) the individuals who participated in the CPHMS baseline survey; * (2) their ID number and phone number are available; * (3) sign the informed consent.
Exclusion criteria
* (1) incapable of taking pre- and post-bronchodilator spirometry tests; * (2) request to withdraw the informed consent; * (3) terminate due to medical or ethical considerations judged by the investigators and/or ethics committee.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurrence of multimorbidities | Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS) | Occurrence of chronic respiratory diseases, cardiovascular and cerebrovascular diseases, malignant tumors, and/or metabolic diseases, etc. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes of lung function, forced expiratory volume in one second (FEV1) | Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS) | Changes of pre- and post-bronchodilator spirometry test indices, FEV1 |
| Changes of lung function, forced vital capacity (FVC) | Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS) | Changes of pre- and post-bronchodilator spirometry test indices, FVC |
| Changes of lung function, FEV1/FVC | Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS) | Changes of pre- and post-bronchodilator spirometry test indices, FEV1/FVC |
| Changes of lung function, the percentage of measured FEV1 value to the predicted value (FEV1%pred) | Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS) | Changes of pre- and post-bronchodilator spirometry test indices, FEV1%pred |
Countries
China
Outcome results
None listed